Allogeneic transplantation for primary myelofibrosis with BM, peripheral blood or umbilical cord blood: an analysis of the JSHCT

[1]  A. Tefferi,et al.  Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management , 2013 .

[2]  A. Mead,et al.  Allogeneic Stem Cell Transplantation for Myelofibrosis in 2012 , 2012, British journal of haematology.

[3]  S. Verstovsek,et al.  Janus kinase Inhibition and its effect upon the therapeutic landscape for myelofibrosis: from palliation to cure? , 2012, British journal of haematology.

[4]  N. Kröger,et al.  Risk models predicting survival after reduced‐intensity transplantation for myelofibrosis , 2012, British journal of haematology.

[5]  H. Deeg,et al.  The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation. , 2012, Blood.

[6]  K. Ballen.  How to manage the transplant question in myelofibrosis , 2012, Blood Cancer Journal.

[7]  R. Porcher,et al.  Retrospective study of allogeneic haematopoietic stem-cell transplantation for myelofibrosis , 2011, Bone Marrow Transplantation.

[8]  M. Griesshammer,et al.  Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  F. Passamonti,et al.  DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Bernard,et al.  Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM‐TC) , 2011, British journal of haematology.

[11]  Y. Hildebrandt,et al.  Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis. , 2010, Blood.

[12]  N. Russell,et al.  The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study , 2010, Bone Marrow Transplantation.

[13]  Koichi Takahashi,et al.  Successful engraftment after reduced-intensity umbilical cord blood transplantation for myelofibrosis. , 2010, Blood.

[14]  M. Cazzola,et al.  A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). , 2010, Blood.

[15]  G. Barosi,et al.  Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type , 2010, Bone Marrow Transplantation.

[16]  N. Kröger,et al.  Outcome of transplantation for myelofibrosis. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[17]  H. Einsele,et al.  Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. , 2009, Blood.

[18]  B. Sandmaier,et al.  Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[19]  H. Deeg,et al.  Allogeneic hematopoietic cell transplantation for patients with myelofibrosis , 2009, Current opinion in hematology.

[20]  R. Mesa,et al.  New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. , 2008, Blood.

[21]  R. Fanin,et al.  Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO) , 2008, Haematologica.

[22]  D. Rondelli.  Allogeneic hematopoietic stem cell transplantation for myelofibrosis , 2008, Haematologica.

[23]  K. Kawa,et al.  Unification of Hematopoietic Stem Cell Transplantation Registries in Japan and Establishment of the TRUMP System , 2007, International journal of hematology.

[24]  F. M. Stewart,et al.  Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[25]  L. Nilsson,et al.  Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced‐intensity conditioning regimens , 2006, British journal of haematology.

[26]  R. Hoffman,et al.  Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. , 2005, Blood.

[27]  J. Panse,et al.  Pilot study of reduced‐intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis , 2005, British journal of haematology.

[28]  N. Kröger,et al.  Dose‐reduced conditioning regimen followed by allogeneic stem cell transplantation in patients with myelofibrosis with myeloid metaplasia , 2002, British journal of haematology.

[29]  A. Verma,et al.  Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. , 2002, Blood.

[30]  A. Tefferi.  Myelofibrosis with myeloid metaplasia. , 2000, The New England journal of medicine.

[31]  J Crowley,et al.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.

[32]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.

[33]  K. Sullivan,et al.  Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. , 1980, The American journal of medicine.

[34]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[35]  G. Dogliotti.  [Idiopathic myelofibrosis]. , 1968, Minerva medica.

[36]  D.,et al.  Regression Models and Life-Tables , 2022 .